Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

被引：0
|
作者：
Moussa, Charbel [1 ]
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
来源：
ANNALS OF NEUROLOGY | 2020年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
535
引用
收藏
页码：S100 / S100
页数：1
相关论文
共 50 条
  • [1] Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial
    Butchart, Joseph
    Brook, Laura
    Hopkins, Vivienne
    Teeling, Jessica
    Puentener, Ursula
    Culliford, David
    Sharples, Richard
    Sharif, Saif
    McFarlane, Brady
    Raybould, Rachel
    Thomas, Rhodri
    Passmore, Peter
    Perry, V. Hugh
    Holmes, Clive
    NEUROLOGY, 2015, 84 (21) : 2161 - 2168
  • [2] ETANERCEPT IN ALZHEIMER DISEASE: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 2 TRIAL
    Tufan, Ayse N.
    Tufan, Fatih
    NEUROLOGY, 2015, 85 (23) : 2083 - 2084
  • [3] A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
    Turner, R. Scott
    Thomas, Ronald G.
    Craft, Suzanne
    van Dyck, Christopher H.
    Mintzer, Jacobo
    Reynolds, Brigid A.
    Brewer, James B.
    Rissman, Robert A.
    Raman, Rema
    Aisen, Paul S.
    NEUROLOGY, 2015, 85 (16) : 1383 - 1391
  • [4] Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial
    Henderson, VW
    Paganini-Hill, A
    Miller, BL
    Elble, RJ
    Reyes, PF
    Shoupe, D
    McCleary, CA
    Klein, RA
    Hake, AM
    Farlow, MR
    NEUROLOGY, 2000, 54 (02) : 295 - 301
  • [5] Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial
    Hannestad, Jonas
    Duclos, Tiffanie
    Chao, Whitney
    Koborsi, Katie
    Klutzaritz, Vicki
    Beck, Brian
    Patel, Ashok K.
    Scott, James
    Thein, Stephen G.
    Cummings, Jeffrey L.
    Kay, Gary
    Braithwaite, Steven
    Nikolich, Karoly
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (04) : 1649 - 1662
  • [6] A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
    Sano, M.
    Bell, K. L.
    Galasko, D.
    Galvin, J. E.
    Thomas, R. G.
    van Dyck, C. H.
    Aisen, P. S.
    NEUROLOGY, 2011, 77 (06) : 556 - 563
  • [7] A randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease
    Profenno, L
    Jakimovich, L
    Holt, C
    Porsteinsson, A
    Tariot, P
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 351 - 352
  • [8] A randomized, double-blind, placebo-controlled trial to assess biomarker outcomes, safety, and tolerability of lithium carbonate in outpatients with probable Alzheimer's disease
    Tarriot, Pierre
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S55 - S55
  • [9] Efficacy and Safety of Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Crohn's Disease
    Chowla, Navreet M.
    Tariq, Raseen
    Aggarwal, Manik
    Loftus, Edward V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S820 - S821
  • [10] Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent
    M. Panisset
    S. Gauthier
    H. Moessler
    M. Windisch
    Journal of Neural Transmission, 2002, 109 : 1089 - 1104
12345